Human Genome Sciences Inc. (Nasdaq: HGSI) will deliver 20,000 doses of its anthrax infection treatment ABthrax to the U. S. government. Shares of the biopharmaceutical surged 57 cents to close at $2.38.
Human Genome To Deliver Anthrax Treatment
February 02, 2009 at 16:42 PM EST
